Sight Sciences operates through two primary business segments: Surgical Glaucoma and Dry Eye. The Surgical Glaucoma segment, which generates the majority of the company's revenue, features the OMNI Surgical System, a single-use device designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This segment also includes the SION Surgical Instrument, a bladeless device used to excise trabecular meshwork during ophthalmic procedures. The Dry Eye segment offers the TearCare System, a wearable, office-based thermal eyelid technology that applies localized heat to treat meibomian gland dysfunction. The company distributes its products primarily in the United States through a direct sales force and a network of distributors. By focusing on interventional technologies, Sight Sciences aims to provide alternatives to traditional pharmaceutical treatments and highly invasive surgeries.
